Progenics Pharmaceuticals reports third quarter results
Yahoo! FinanceProgenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced its results of operations for the third quarter ended September 30, 2003 and first nine months of 2003. Revenues for the third quarter ended September 30, 2003 totaled $1.9 million compared to $2.7 million for the same quarter in 2002. Revenues primarily reflect funding received by the Company from government grants and contracts and revenues from research and development services rendered to the Company's joint venture with Cytogen Corporation. In September, Progenics was awarded a contract from the National Institutes of Health (NIH), an agency of the Department of Health and Human Services, to develop a novel vaccine against the human immunodeficiency virus (HIV).
—Posted: October 31, 2003
More news headlines: This week | Last week | Search archive